| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8615451 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 33 Pages |
Abstract
CD20 expression in adult ALL-B is associated with decreased OS. Treatment with rituximab can increase OS, EFS, and CR in the 18- to 39-year age group.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Reibán-Espinoza Esteban, Bourlon Christianne, Aguayo Alvaro, Roberta Demichelis-Gómez,